TrialPrimary completion date
Recorded edit− Previous value
2026-08
+ Updated value
2027-02
NCT07332000Phase 2Recruiting
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Study sponsor: Candel Therapeutics, Inc. · CADL
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2027-02Estimated
Enrollment · participants45Estimated
Source updated2026-09-15Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Biodistribution of aglatimagene besadenovec; measure: Biomarkers of immune activation and tumor burden; measure: Biomarkers of immune activation and tumor burden; measure: Biomarkers of immune activation and tumor burden
+ Updated value
measure: Biodistribution of aglatimagene besadenovec
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count
Recorded edit− Previous value
count: 30; type: ESTIMATED
+ Updated value
count: 45; type: ESTIMATED
Primary completion date
Recorded edit− Previous value
2026-06
+ Updated value
2026-08